Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M
Aquestive Therapeutics announced, in response to Indivior PLC's press release issued earlier today of Indivior's intent to cease production of its authorized generic buprenorphine-naloxone film product, that the company is reaffirming its full year 2019 total revenue guidance. Full year 2019 total revenue is now expected to be at the top end of the company's guidance range of $38M-$45M. Full year 2019 revenue from the company's Suboxone franchise is expected to be at the top end of its guidance range of $29M-$32M. As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone.